Two-dimensional (2D) cell cultures have been extensively used as tools to predict preclinical outcomes before proceeding to expensive animal studies despite their limited success in replicating in vivo studies.

The development of a 30-color immunophenotyping panel using the Cytek Aurora™ Spectral Flow Cytometer has enabled detailed profiling of T cell, NK and B cell subsets, along with their functional states.

PGDx elio plasma focus Dx, a liquid biopsy next-generation sequencing (NGS) assay, detects 33 genes including difficult to detect structural variants with high sensitivity, specificity, accuracy and reproducibility.

SQA 2025 -- Vulnerable populations are groups of people that are at an increased risk and require additional protections when conducting clinical trials. There are many vulnerable groups in the population, but this poster will focus on children, older adults, pregnant women and people with rare diseases.

SQA 2025 -- It is an industry expectation that sponsors will conduct a quality audit for contract research organizations (CROs) performing preclinical studies. As a client audit host, there are things you can do to support a successful audit. Preparation for the audit ahead of time is key. What can be done to prepare for a sponsor audit?

SQA 2025 -- The purpose of the phase audit is to monitor each study to provide assurance to test facility management. The phase audit report is sent to both the study director and to test facility management.

SQA 2025 -- A nonclinical laboratory study was conducted following the Sponsor-approved protocol and the data has been collected. As the Study Director tabulates the data and draws their conclusions, the Sponsor asked to review drafts of the main study report and all principal investigators/contributing scientist reports.